产品
编 号：F194312
分子式：C17H12F4N2O2S
分子量：384.35
分子式：C17H12F4N2O2S
分子量：384.35
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 162054-19-5
产品详情
生物活性：
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect.
体内研究：
SC-58125 (10 mg/kg; i.p. every 48 h) inhibits the growth of established colorectal cancer xenografts in mice.SC-58125 (10 mg/kg; a single i.p.) reduces tumor PGE2 levels in mice.SC-58125 (10 mg/kg; a single i.p.) does not change the tumor levels of COX-1 and COX-2 protein in mice.Animal Model:Athymic Sprague-Dawley mice are injected HCA-7 cells
Dosage:10 mg/kg
Administration:I.p. every 48 h; at the time of tumor implantation or 2 and 4 weeks later
Result:Decreased the tumor growth rates significantly.
体外研究：
SC-58125 (0.001-100 μM) has a high degree of selectivity for the inducible form of COX-2 (IC50=1 μM) over the COX-1 (IC50>100 μM).SC-58125 (10 μM; 20-140 s) is time-dependent and is complete by 1 min, with a half-maximal inhibition at 20 s.SC-58125 (25-100 μM; 3 d) inhibits the in vitro growth of HCA-7 and LLC cells.SC-58125 (100 μM; 12 h) induces G2 arrest in LLC cells.SC-58125 (25-100 μM; 3 d) decreases p34cdc2 levels in HCA-7 cells.SC-58125 (100 μM; 24 or 72 h) does not induce apoptosis of HCA-7 and LLC cells.
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect.
体内研究：
SC-58125 (10 mg/kg; i.p. every 48 h) inhibits the growth of established colorectal cancer xenografts in mice.SC-58125 (10 mg/kg; a single i.p.) reduces tumor PGE2 levels in mice.SC-58125 (10 mg/kg; a single i.p.) does not change the tumor levels of COX-1 and COX-2 protein in mice.Animal Model:Athymic Sprague-Dawley mice are injected HCA-7 cells
Dosage:10 mg/kg
Administration:I.p. every 48 h; at the time of tumor implantation or 2 and 4 weeks later
Result:Decreased the tumor growth rates significantly.
体外研究：
SC-58125 (0.001-100 μM) has a high degree of selectivity for the inducible form of COX-2 (IC50=1 μM) over the COX-1 (IC50>100 μM).SC-58125 (10 μM; 20-140 s) is time-dependent and is complete by 1 min, with a half-maximal inhibition at 20 s.SC-58125 (25-100 μM; 3 d) inhibits the in vitro growth of HCA-7 and LLC cells.SC-58125 (100 μM; 12 h) induces G2 arrest in LLC cells.SC-58125 (25-100 μM; 3 d) decreases p34cdc2 levels in HCA-7 cells.SC-58125 (100 μM; 24 or 72 h) does not induce apoptosis of HCA-7 and LLC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备